Abstract: An expandable while-in-use cover includes: a cap having a pair of cap side walls, a first cap end wall, a second cap end wall and a top wall, which define a cap opening and a cap interior; a base having a pair of base side walls, a first base end wall, a second base end wall and a back wall, which define a base opening and a base exterior, wherein the base side walls and base end walls correspond to the cap side walls and cap end walls and wherein the cover is adapted to slidably and/or telescopically receive the base; a first and second prong on the interior of each of the cap side walls near the first and second cap end walls; a first and second slotted track on the exterior of each of the base side walls near the base end walls, wherein the first slotted track of each base side wall is adapted to receive the first prong of each cap side wall and the second slotted track of each base side wall is adapted to receive the second prong of each cap side wall; and an aperture in the back wall for accessing an ele

Abstract: An expandable while-in-use cover includes: a cap having a pair of cap side walls, a first cap end wall, a second cap end wall and a top wall, which define a cap opening and a cap interior; a base having a pair of base side walls, a first base end wall, a second base end wall and a back wall, which define a base opening and a base exterior, wherein the base side walls and base end walls correspond to the cap side walls and cap end walls and wherein the cover is adapted to slidably and/or telescopically receive the base; a first and second prong on the interior of each of the cap side walls near the first and second cap end walls; a first and second slotted track on the exterior of each of the base side walls near the base end walls, wherein the first slotted track of each base side wall is adapted to receive the first prong of each cap side wall and the second slotted track of each base side wall is adapted to receive the second prong of each cap side wall; and an aperture in the back wall for accessing an ele

Abstract: An expandable while-in-use cover includes: a cap having a pair of cap side walls, a first cap end wall, a second cap end wall and a top wall, which define a cap opening and a cap interior; a base having a pair of base side walls, a first base end wall, a second base end wall and a back wall, which define a base opening and a base exterior, wherein the base side walls and base end walls correspond to the cap side walls and cap end walls and wherein the cover is adapted to slidably and/or telescopically receive the base; a first and second prong on the interior of each of the cap side walls near the first and second cap end walls; a first and second slotted track on the exterior of each of the base side walls near the base end walls, wherein the first slotted track of each base side wall is adapted to receive the first prong of each cap side wall and the second slotted track of each base side wall is adapted to receive the second prong of each cap side wall; and an aperture in the back wall for accessing an ele

Abstract: The present invention relates to new lupane dervivatives of the general formula: ##STR1## to their salts, to their preparation and to the pharmaceutical compositions which contain them.

Abstract: Pharmaceutical compositions are disclosed. They are useful for the treatment of medical conditions associated with the effects of glutamate, comprise as active principle, at least one compound of formula: ##STR1## or a salt thereof, in which either R.sub.1 represents polyfluoroalkoxy, 2,2,2-trifluoroethyl, pentafluoroethyl, tert-butyl, trimethylsilyl or trifluoromethylthio and R.sub.2 and R.sub.3 represent hydrogen,or R.sub.1 represents polyfluoroalkoxy, R.sub.2 represents hydrogen and R.sub.3 represents alkyl, amino, alkoxy, phenyl, phenylalkyl, dimethylamino or dialkylaminoakylthio,or R.sub.1 represents polyfluoroalkoxy, R.sub.2 represents amino and R.sub.3 represents hydrogen, with the exception of 6-trifluoromethoxy-2-benzothiazolamine.

Abstract: Process for preparing (1R,2R)-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamide 1-oxides of general formula: ##STR1## (R.sub.1 =alkyl containing 1 to 4 carbon atoms), by the action of an alkyl isothiocyanate on the 1R,2R and 1R,2S sulphoxides of formulae: ##STR2## employed alone or mixed, the (1R,2R)-2-(3-pyridyl)tetrahydrothiopyran-2-carbothioamide 1-oxides thereby obtained and pharmaceutical compositions containing them.(1R,2R)-2-(3-Pyridyl)tetrahydrothiopyran-2-carbothioamide 1-oxides are especially useful as antihypertensives.

Abstract: New derivatives of formula (I) in which R.sub.1 =H, halogen, alkyl, alkyloxy, CF.sub.3, NH.sub.2, alkylamino, dialkylamino, OH, CH, phenyl or phenoxy, Ar=phenyl, naphthyl, pyridyl, quinolyl, isoquinolyl, thienyl, thieno[2,3-b]thienyl or thieno[3,2-b]thienyl (these groups optionally substituted with halogen, alkyl, alkyloxy, CF.sub.3, NH.sub.2, alkylamino, dialkylamino, OH or CN), p=0, 1 or 2, andA--either Z=valency bond and R.sub.2 =HB--or Z=valency bond and R.sub.2 =pyridyl, quinuclidinyl, 3-pyrrolidinyl, 3- or 4-piperidyl (these groups optionally being substituted with alkyl, hydroxyalkyl, phenyl or phenylalkyl)C--or Z=alkylene radical (1 to 4C) and R.sub.2 =2-, 3- or 4-pyridyl, 3-quinuclidinyl, 2- or 3-pyrrolidinyl, 2-, 3- or 4-piperidyl (optionally substituted with alkyl, hydroxyalkyl, phenyl or phenylalkyl) or R.sub.2 =CON(R.sub.3)(R.sub.4) wherea) either R.sub.3 and R.sub.4 form a piperazine optionally substituted with alkyl, hydroxyalkyl, pyridyl, phenyl or phenylalkyl,b) or R.sub.

Abstract: Tripeptides of the general formula: ##STR1## wherein the symbols R, which may be the same or different represent hydrogen or a fatty acid residue (at least one of them representing a fatty acid residue), R.sub.1 represents hydroxy, amino or alkoxy and R.sub.2 and R.sub.3, which may be the same or different, represent hydrogen, carboxy, carbamoyl or alkoxycarbonyl radical (with the proviso that R.sub.2 and R.sub.3 cannot simultaneously represent a hydrogen atom), the alanine moiety being in the L form, the glutamic acid moiety being in the D form, the lysine moiety (when R.sub.2 or R.sub.3 =a hydrogen atom) being in the L form and the 2,6-diaminopimelic acid moiety or its derivatives (when R.sub.2 and/or R.sub.3 =carboxy, carbamoyl or alkoxycarbonyl) being in the D,D, L,L, D,D/L,L (racemic) or D,L (meso) form, and salts thereof, possess immunological adjuvant and immunostimulant activity.

Abstract: N.sup.6 -Benzyloxycarbonyl-2,6-diaminopimelamic acid in L,L or D,D or racemic form is prepared by amidation of O.sup.1 -p-nitrobenzyl-N.sup.2 -benzyloxycarbonyl-2,6-diaminopimelic acid in L,L or D,D or racemic form.

Abstract: A compound of the general formula I: ##STR1## in which Ar is a pyridyl, quinolinyl, isoquinolinyl, naphthyridinyl, pyrimidyl, quinazolinyl, thiazolyl, benzothiazolyl, imidazolyl, benzimidazolyl, oxazolyl, benzoxazolyl, thienyl, benzothienyl or naphthyl group; optionally substituted with one or more halogen or alkyl, alkyloxy, alkylthio, trifluoromethyl, amino, alkylamino, dialkylamino, hydroxy, cyano, alkylsulphinyl, alkylsulphonyl, sulphamido, alkylsulphamido, dialkylsulphamido, alkylcarbonyl, benzoyl, alkyloxycarbonyl, carboxy, phenoxycarbonyl, alkylcabonyloxy, benzoyloxy, alkylcarbonylamino, benzamido, phenyl, benzyl, phenoxy or phenylthio group, provided that (i) when Ar is a pyridyl group, the pyridyl group must be substituted, (ii) an alkyl moiety contains 1 to 4 straight- or branched chain carbon atoms; (iii) a phenyl moiety may be unsubstituted or substituted with one or more halogen or alkyl, alkyloxy, alkylthio, trifluoromethyl, amino, alkylamino, dialkylamino, hydroxy, cyano, phenyl or benzyl group

Abstract: A compound of the general formula I; ##STR1## in which R is hydrogen or a halogen or an alkyl, alkyloxy, alkylthio, trifluoromethyl, amino, alkylamino, dialkylamino, hydroxy, cyano, carboxy, alkylsulphinyl, alkylsulphonyl, sulphamido, alkylsulphamido, dialkylsulphamido, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, phenylcarbamoyl, diphenylcarbamoyl, pyridylcarbamoyl, dipyridylcarbamoyl, benzyl, alkylcarbonyl, benzoyl, alkyloxycarbonyl, phenoxycarbonyl, alkylcarbonyloxy, benzoyloxy, alkylcarbonylamino, benzamido, phenyl, phenoxy or phenylthio group, X is oxygen or sulphur or an imino, alkylimino, phenylimino, benzylimino, sulphinyl, sulphonyl, carbonyl, carbonylmethylene, methylenecarbonyl, carbonylvinylene or vinylenecarbonyl group, or X represents a valency bond or a straight-chain alkylene group containing 1 to 4 carbon atoms and Ar is a phenyl, naphthyl, pyridyl, quinolinyl, isoquinolinyl, thienyl, benzothienyl, thieno[3,2-b]thien-2-yl or thieno[2,3-b]thien-2-yl group, it being possible for the group Ar to

Abstract: Thioformamide derivatives of the formula: ##STR1## wherein R is hydrogen or alkyl (1 to 4 C), Het is pyridin-3-yl[optionally substituted by alkyl (1 to 4 C) or a halogen], quinolin-3-yl, pyridazin-4-yl, pyrimidin-5-yl, thiazol-5-yl, thieno[2,3-b]pyridin-5-yl or thieno[3,2-b]pyridin-6-yl, and Y is a valency bond or a methylene radical, are new compounds, which are particularly useful as antihypertensive agents.

Abstract: Tetrapeptides and pentapeptides of the formula: ##STR1## wherein R represents hydrogen or a fatty acid residue, R.sub.1 represents hydroxy, amino, alkoxy of 1 to 4 carbon atoms, optionally substituted by phenyl or nitrophenyl, one of R.sub.2 and R.sub.4 represents hydrogen, carboxy, carbamoyl, alkoxycarbonyl of 2 to 5 carbon atoms, optionally substituted by phenyl or nitrophenyl, or a N-carbonylglycine or N-carbonyl-D-alanine radical optionally esterified by alkyl of 1 to 4 carbon atoms (which is optionally substituted by phenyl or nitrophenyl) and the other symbol represents hydrogen, carboxy, carbamoyl, or alkoxycarbonyl fof 2 to 5 carbon atoms, optionally substituted by phenyl or nitrophenyl, and R.sub.3 represents hydrogen, a fatty acid residue or a glycyl or D-alanyl moiety in which the amine group is optionally substituted by a fatty acid residue, it being understood that R.sub.2 and R.sub.4 cannot simutaneously represent hydrogen, that at least one of R.sub.2, R.sub.3 and R.sub.

Abstract: The invention provides novel pyrrole derivatives of formula: ##STR1## in which R'=H, alkyl or phenyl optionally substituted by halogen, alkyl, alkyloxy or alkylthio, Z=0 or S, p=0 or 1, andeither A is a heterocyclic ring such that it forms, with pyrrole, a 1H,3H-pyrrolo[1,2-c]thiazole, 2,3-dihydro-1H-pyrrolizine optionally substituted by OH, 5,6,7,8-tetrahydroindolizine, 1,2-dihydro-4H-pyrrolo[1,2-c]-1,3-thiazine, 2,3-dihydropyrrolo[2,1-b]thiazole, 1H,3H-pyrrolo[1,2-c]oxazole, 1,2-dihydro-4H-pyrrolo]1,2-c]-1,3-oxazine or 2,3-dihydropyrrolo[2,1-b]oxazole ring system, n=0 or 1, Het=3-pyridyl or 5-thiazolyl, and(1) either R=H, halogen, alkyl or phenyl optionally substituted by halogen, alkyloxy or alkylthio and Y=alkyl or phenyl optionally substituted by halogen, alkyl, alkyloxy or alkylthio, or Y=--NR.sub.1 R.sub.2 with:either R.sub.1 =H and R.sub.2 =unsubstituted alkyl, cycloalkyl (C.sub.3 -C.sub.6), alkenyl (C.sub.2 -C.sub.4), alkynyl (C.sub.3 -C.sub.

Abstract: Thioformamide derivatives of formula: ##STR1## in which R is hydrogen or alkyl (1 to 4 C), R.sub.1 is alkyl (1 to 4 C), and X denotes sulphur or oxygen and Y is sulphur, oxygen, methylene radical, or, when X is oxygen, a valency bond, are inhibitors of gastric secretion and therefore useful in the treatment of gastric ulcers. They may be made by reaction of an amine R--NH.sub.

Abstract: Antithrombotics of the formula ##STR1## in which A=S, SO or SO.sub.2, R.sub.3 =H, alkyl or substituted or unsubstituted phenyl, X=O, S, NH or variously substituted nitrogen, p is 0 or 1 and y=H, NH.sub.2, or various substituted amines.

Abstract: Thioformamide derivatives of the formula: ##STR1## wherein R is hydrogen or alkyl (1 to 4 C), Het is pyridin-3-yl [optionally substituted by alkyl (1 to 4 C) or a halogen], quinolin-3-yl, pyridazin-4-yl, pyrimidin-5-yl, thiazol-5-yl, thieno[2,3-b]pyridin-5-yl or thieno[3,2-b]pyridin-6-yl, and Y is a valency bond or a methylene radical, are new compounds, which are particularly useful as antihypertensive agents.

Abstract: Pyrrolidine derivatives of the formula: ##STR1## wherein X represents an oxygen or sulphur atom, R represents a hydrogen atom or an alkyl radical, R.sub.o represents a hydrogen atom, an alkyl radical or a phenyl radical optionally substituted by a halogen atom or by an alkyl, alkoxy, alkylthio or nitro radical, A represents a nitrogen atom or a radical .dbd.CH--, the symbol Y represents a hydrogen or halogen atom or an alkyl, alkoxy, alkylthio, alkylcarbonyl, nitro, amino, alkylcarbonylamino, alkylamino, dialkylamino, alkylsulphinyl, alkylsulphonyl, alkoxycarbonyl, cyano, trifluoromethyl, hydroxy, mercapto, alkylcarbonyloxy or alkylcarbonylthio radical, n represents zero or 1, and p represents 1, 2 or 3, it being understood that the alkyl and alkoxy radicals, and alkyl and alkoxy moieties of any of the aforementioned groups, contain from 1 to 4 carbon atoms are new therapeutically useful compounds, more particularly useful as antidepressants.

Abstract: Antithrombotics of the formula: ##STR1## wherein A is S, SO or SO.sub.2 ; R.sub.3 is H, alkyl or substituted or unsubstituted phenyl; p is zero or 1; X is O, S, N or variously substituted nitrogen; Y is H or various substituted amines.

Abstract: The invention provides new derivatives of the formula: ##STR1## in which either (a) Y=COOH or a radical of the formula (II), in which R.sub.2 =alkyl or benzyl, A=a sulphur atom, m=1, n=0, R=pyridin-3-yl and R.sub.1 =H, or (b) Y=CN, COOH or a radical of the formula ##STR2## defined as above, A=S, O or CH.sub.2, m=1 or 2 and n=0, 1 or 2, (m+n) being 1, 2 or 3, R=H, alkyl or phenyl (optionally substituted by halogen, alkyl, alkoxy or CF.sub.3) and R.sub.1 =a radical of the formula ##STR3## in which p=0 or 1, the alkyl radicals and alkyl portions being straight-chain or branched-chain and containing 1 to 4 carbon atoms each. Processes for the production of these compounds are described. They are useful as intermediates for the preparation of new medicaments.